Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$38.4 million.

  • Sutro Biopharma's Free Cash Flow rose 4117.29% to -$38.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$225.1 million, marking a year-over-year decrease of 10614.55%. This contributed to the annual value of -$194.6 million for FY2024, which is 6789.12% down from last year.
  • Latest data reveals that Sutro Biopharma reported Free Cash Flow of -$38.4 million as of Q3 2025, which was up 4117.29% from -$44.8 million recorded in Q2 2025.
  • Sutro Biopharma's Free Cash Flow's 5-year high stood at $65.1 million during Q3 2022, with a 5-year trough of -$72.8 million in Q4 2024.
  • Its 5-year average for Free Cash Flow is -$29.7 million, with a median of -$32.8 million in 2021.
  • In the last 5 years, Sutro Biopharma's Free Cash Flow skyrocketed by 32146.04% in 2022 and then crashed by 67640.73% in 2024.
  • Quarter analysis of 5 years shows Sutro Biopharma's Free Cash Flow stood at -$24.1 million in 2021, then dropped by 12.91% to -$27.2 million in 2022, then surged by 146.38% to $12.6 million in 2023, then plummeted by 676.41% to -$72.8 million in 2024, then soared by 47.2% to -$38.4 million in 2025.
  • Its Free Cash Flow was -$38.4 million in Q3 2025, compared to -$44.8 million in Q2 2025 and -$69.1 million in Q1 2025.